SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Charts on Near Term Uotrends

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RockyBalboa who wrote (1165)7/1/2009 6:00:36 PM
From: Jibacoa  Read Replies (3) of 1404
 
BORL, yes it continues with the UT and opened with another UG.

But volume remains moderate, nothing like the 22,644,700 traded on May 6, and the steady trend after the UG doesn't gives any opportunities for intraday trading.<g>

bigcharts.marketwatch.com

I was playing today with ANDR which had a nice move from the $0.05 level after the news that some of its microphones are been installed in HP computers. <g>
finance.yahoo.com

I already had a few thousand shrs, but was able to buy some more after the news. It had a nice % gain today and volume was good.<g>
bigcharts.marketwatch.com

Also was able to pick some SEPR which has already closed its Jan2 UG and is now starting to move above its Feb13 H
bigcharts.marketwatch.com

Although it has resistance at the $20 level, it seems it could double if the EE come out as projected.<g>
bigcharts.marketwatch.com

As I am writing, the stock seems to be holding today's moderate gains AHs in spite of announcing, after the marked closed, that it has completed the analysis of the preliminary results of a PII evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive Disorder, which didn't meet the primary efficacy endpoint.But they said that the preliminary data are inconclusive pending further investigation of the dose exposure relationship.<g>

The pharmacological profile of SEP-225289 is distinct from all other currently approved antidepressant agents due to its significant affinity for the dopamine transporter as well as its high potency reuptake inhibition at the serotonin and norepinephrine transporters.

In 2008 and early this Yr., SEPR completed 2 pediatric studies of LUNESTA in response to a request from the FDA.
In April it initiated 2 additional pediatric studies.

Well, I was stopped out the SEPR shrs I picked, as the stock started to respond badly to the AHs announcement and it seems that it will start with a DG tomorrow.<g>

Bernard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext